Company intelligence / Profile preview
Outpace Bio
Seattle, Washington, USAoutpacebio.com ↗
- Ownership
- Private
- Employees
- ~53
- Development stage
- Preclinical
01
Overview
Lead program OPB-101, a mesothelin-specific CAR T cell therapeutic candidate, demonstrates complete elimination of solid tumors in stringent in vivo models at very low treatment doses (as low as 50,000 cells) and is on track to enter the clinic in 2025
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyCAR-T cell therapyEngineered T cell therapies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Lyell Immunopharma (partnership looking at tumor-restricted IL-12)
Beyond the preview
Go deeper on Outpace Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Outpace Bio.